Klio Pharma Profile
Key Indicators
- Authorised Capital ₹ 9.00 Cr
as on 30-10-2024
- Paid Up Capital ₹ 4.77 Cr
as on 30-10-2024
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2355.59%
(FY 2023)
- Profit -187.48%
(FY 2023)
- Ebitda -224.18%
(FY 2023)
- Net Worth -30.74%
(FY 2023)
- Total Assets 46.30%
(FY 2023)
About Klio Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 Cr and a paid-up capital of Rs 4.77 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Klio Pharma Private Limited India is Venkat Sunkavalli as CEO. Venkat Sunkavalli and Sunkavalli Benerjee serve as directors at the Company.
- CIN/LLPIN
U24303TG2020PTC139831
- Company No.
139831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Klio Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkat Sunkavalli | CEO | 05-Jan-2023 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkat Sunkavalli  | Director | 02-Jan-2021 | Current |
Sunkavalli Benerjee  | Director | 16-Mar-2020 | Current |
Financial Performance and Corporate Structure Insights of Klio Pharma.
Klio Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 2355.59% increase. The company also saw a substantial fall in profitability, with a 187.48% decrease in profit. The company's net worth observed a substantial decline by a decrease of 30.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Klio Pharma?
In 2023, Klio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Klio Pharma?
Klio Pharma has a workforce of 19 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Klio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Klio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
